PDCD1 and neoplasm: This trend in cell ratios reflects the possibility that CD127-expressing T cells and KLRG1-expressing CD8+ T cells are the main immune cell types mediating anti-tumor immunity after the addition of PD-1 blockade to neoadjuvant chemotherapy.